You are currently on the new version of our website. Access the old version .

437 Results Found

  • Article
  • Open Access
2 Citations
4,454 Views
17 Pages

30 January 2025

Background/Objectives: Long-term peritoneal dialysis (PD) often results in peritoneal damage and fibrosis, impairing peritoneal membrane function and leading to ultrafiltration failure. This study aimed to explore the therapeutic potential of ninteda...

  • Review
  • Open Access
2 Citations
5,430 Views
20 Pages

Intestinal Fibrosis in Crohn’s Disease: Pathophysiology, Diagnosis, and New Therapeutic Targets

  • Fotios S. Fousekis,
  • Konstantinos Mpakogiannis,
  • Ioanna Nefeli Mastorogianni,
  • Georgios D. Lianos,
  • Dimitrios K. Christodoulou and
  • Konstantinos H. Katsanos

8 June 2025

Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract that often leads to intestinal fibrosis, an irreversible complication associated with strictures and the need for surgical intervention. Fibrosis occurs due t...

  • Review
  • Open Access
18 Citations
11,705 Views
16 Pages

20 February 2024

Developing effective anti-fibrotic therapies for heart diseases holds the potential to address unmet needs in several cardiac conditions, including heart failure with preserved ejection fraction, hypertrophic cardiomyopathy, and cardiotoxicity induce...

  • Review
  • Open Access
38 Citations
8,756 Views
24 Pages

Novel Therapies for the Treatment of Cardiac Fibrosis Following Myocardial Infarction

  • Kamila Raziyeva,
  • Yevgeniy Kim,
  • Zharylkasyn Zharkinbekov,
  • Kamila Temirkhanova and
  • Arman Saparov

Cardiac fibrosis is a common pathological consequence of most myocardial diseases. It is associated with the excessive accumulation of extracellular matrix proteins as well as fibroblast differentiation into myofibroblasts in the cardiac interstitium...

  • Review
  • Open Access
8 Citations
3,340 Views
14 Pages

The Role of Cardiac Fibroblast Heterogeneity in Myocardial Fibrosis and Its Novel Therapeutic Potential

  • Isotta Chimenti,
  • Francesca Pagano,
  • Claudia Cozzolino,
  • Francesca Icolaro,
  • Erica Floris and
  • Vittorio Picchio

Cardiac fibrosis is a key physiopathological process underlying the progression of virtually all heart diseases and related conditions, including myocardial infarction, pressure overload, and heart failure. Once regarded as a homogeneous and passive...

  • Article
  • Open Access
591 Views
34 Pages

5 December 2025

Background: Liver fibrosis is a progressive pathological condition characterized by excessive extracellular matrix deposition, driven by activated hepatic stellate cells (aHSCs). Effective therapeutic strategies require targeting aHSCs and agents cap...

  • Review
  • Open Access
2 Citations
3,323 Views
15 Pages

Personalized Antifibrotic Therapy in CKD Progression

  • Charlotte Delrue,
  • Michele F. Eisenga,
  • Joris R. Delanghe and
  • Marijn M. Speeckaert

5 December 2024

Chronic kidney disease (CKD) is a chronic disorder characterized by kidney fibrosis and extracellular matrix accumulation that can lead to end-stage kidney disease. Epithelial-to-mesenchymal transition, inflammatory cytokines, the TGF-β pathway,...

  • Review
  • Open Access
15 Citations
4,911 Views
24 Pages

Chronic kidney disease (CKD) affects 1 in 10 members of the general population, placing these patients at an increasingly high risk of kidney failure. Despite the significant burden of CKD on various healthcare systems, there are no effective cures t...

  • Review
  • Open Access
59 Citations
10,428 Views
19 Pages

Therapeutic Targeting of Intestinal Fibrosis in Crohn’s Disease

  • Giovanni Santacroce,
  • Marco Vincenzo Lenti and
  • Antonio Di Sabatino

26 January 2022

Intestinal fibrosis is one of the most threatening complications of Crohn’s disease. It occurs in more than a third of patients with this condition, is associated with increased morbidity and mortality, and surgery often represents the only ava...

  • Review
  • Open Access
123 Citations
18,384 Views
23 Pages

3 September 2020

Cancer associated fibroblasts (CAF) and the extracellular matrix (ECM) produced by them have been recognized as key players in cancer biology and emerged as important targets for cancer treatment and drug discovery. Apart from their presence in strom...

  • Article
  • Open Access
2 Citations
2,830 Views
18 Pages

The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis

  • Stefano Kette,
  • Nicolò Reccardini,
  • Francesco Salton,
  • Paola Confalonieri,
  • Alessia Andrisano,
  • Maria Chianese,
  • Anna De Nes,
  • Marta Maggisano,
  • Alessandra Galantino and
  • Barbara Ruaro
  • + 8 authors

14 March 2025

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease of unknown aetiology. Evidence on the progression of idiopathic pulmonary fibrosis (IPF) following the introduction of antifibrotic therapies still indicates a ge...

  • Review
  • Open Access
2 Citations
4,139 Views
31 Pages

30 June 2025

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and interstitial lung disease (ILD) represent a complex interplay between autoimmune and fibrotic processes that poses significant diagnostic and therapeutic challenges. The dist...

  • Article
  • Open Access
6 Citations
2,865 Views
13 Pages

Radiation-Induced Fibrotic Tumor Microenvironment Regulates Anti-Tumor Immune Response

  • Jae-Kyung Nam,
  • Ji-Hee Kim,
  • Min-Sik Park,
  • Eun Ho Kim,
  • Joon Kim and
  • Yoon-Jin Lee

19 October 2021

High linear energy transfer (LET) radiation, such as neutron radiation, is considered more effective for the treatment of cancer than low LET radiation, such as X-rays. We previously reported that X-ray irradiation induced endothelial-to-mesenchymal...

  • Review
  • Open Access
59 Citations
7,485 Views
18 Pages

Communication by voice depends on symmetrical vibrations within the vocal folds (VFs) and is indispensable for various occupations. VF scarring is one of the main reasons for permanent dysphonia and results from injury to the unique layered structure...

  • Review
  • Open Access
255 Views
23 Pages

Targeting Cardiac Fibroblast Plasticity for Antifibrotic and Regenerative Therapy in Heart Failure

  • Suchandrima Dutta,
  • Sophie Chen,
  • Waqas Ahmad,
  • Wei Huang,
  • Jialiang Liang and
  • Yigang Wang

8 January 2026

Cardiac fibrosis is a major component of heart failure (HF) and develops when reparative wound healing becomes chronic, leading to excessive extracellular matrix accumulation. Cardiac fibroblasts (CFs), the main regulators of matrix remodeling, are h...

  • Perspective
  • Open Access
40 Citations
6,809 Views
9 Pages

Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?

  • Josef Gillson,
  • Yogambha Ramaswamy,
  • Gurvinder Singh,
  • Alemayehu A. Gorfe,
  • Nick Pavlakis,
  • Jaswinder Samra,
  • Anubhav Mittal and
  • Sumit Sahni

24 May 2020

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid tumors in the world. Currently, there are no approved targeted therapies for PDAC. Mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS) are known to be a major driver o...

  • Article
  • Open Access
1 Citations
3,759 Views
12 Pages

31 January 2023

Chronic obstructive pulmonary disease (COPD) is a lung illness, marked by dyspnea, coughing, and sputum production. Cheonwangbosim-dan (CBD) is a traditional East Asian medicine, consisting of a combination of 15 medicinal herbs, which is frequently...

  • Communication
  • Open Access
43 Citations
4,454 Views
9 Pages

Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy

  • Miriana d’Alessandro,
  • Laura Bergantini,
  • Paolo Cameli,
  • Maria Pieroni,
  • Rosa Metella Refini,
  • Piersante Sestini and
  • Elena Bargagli

9 February 2021

Background: Krebs von den Lungen-6 (KL-6) was suggested as ILD biomarker including idiopathic pulmonary fibrosis (IPF). Lung cancer is one of the most severe comorbidity of IPF patients. This study aims to serially analyze KL-6 in IPF patients after...

  • Article
  • Open Access
29 Citations
5,504 Views
33 Pages

Local Delivery of Pirfenidone by PLA Implants Modifies Foreign Body Reaction and Prevents Fibrosis

  • Alexey Fayzullin,
  • Semyon Churbanov,
  • Natalia Ignatieva,
  • Olga Zakharkina,
  • Mark Tokarev,
  • Daniil Mudryak,
  • Yana Khristidis,
  • Maxim Balyasin,
  • Alexandr Kurkov and
  • Anatoly Shekhter
  • + 5 authors

Peri-implant fibrosis (PIF) increases the postsurgical risks after implantation and limits the efficacy of the implantable drug delivery systems (IDDS). Pirfenidone (PF) is an oral anti-fibrotic drug with a short (<3 h) circulation half-life and s...

  • Review
  • Open Access
24 Citations
16,617 Views
18 Pages

30 March 2023

Sustained hypertension causes structural, functional, and neurohumoral abnormalities in the heart, a disease commonly termed hypertensive heart disease (HHD). Modern concepts of HHD, including processes of remodeling leading to the development of var...

  • Article
  • Open Access
5 Citations
3,165 Views
15 Pages

HSPB5 Inhibition by NCI-41356 Reduces Experimental Lung Fibrosis by Blocking TGF-β1 Signaling

  • Julie Tanguy,
  • Pierre-Marie Boutanquoi,
  • Olivier Burgy,
  • Lucile Dondaine,
  • Guillaume Beltramo,
  • Burhan Uyanik,
  • Carmen Garrido,
  • Philippe Bonniaud,
  • Pierre-Simon Bellaye and
  • Françoise Goirand

24 January 2023

Idiopathic pulmonary fibrosis is a chronic, progressive and lethal disease of unknown etiology that ranks among the most frequent interstitial lung diseases. Idiopathic pulmonary fibrosis is characterized by dysregulated healing mechanisms that lead...

  • Review
  • Open Access
13 Citations
3,784 Views
13 Pages

The prevalence of pulmonary hypertension (PH) complicating interstitial lung diseases (ILDs) is 3.5–15% at an early stage, and up to 90% in ILD patients listed for lung transplantation. In addition, other types of PH may occur in patients with...

  • Article
  • Open Access
3 Citations
2,685 Views
22 Pages

Activin A Inhibitory Peptides Suppress Fibrotic Pathways by Targeting Epithelial–Mesenchymal Transition and Fibroblast–Myofibroblast Transformation in Idiopathic Pulmonary Fibrosis

  • Victor Alexandre F. Bastos,
  • Patrícia Tiemi Fujimura,
  • Aline Gomes de Souza,
  • Emília Rezende Vaz,
  • Natieli Saito,
  • Robinson Sabino-Silva,
  • Luiz Ricardo Goulart and
  • Thulio Marquez Cunha

Idiopathic pulmonary fibrosis (IPF) is a progressive and incurable chronic interstitial lung disease characterized by excessive fibrosis and impaired lung function. Current treatments, such as pirfenidone and nintedanib, slow disease progression but...

  • Article
  • Open Access
1 Citations
1,947 Views
19 Pages

Retrospective Observational Study of Nintedanib in Managing Idiopathic and Progressive Pulmonary Fibrosis in Routine Practice

  • Alessia Giovanna Andrisano,
  • Nadia Castaldo,
  • Francesco Giuliana,
  • Davide Femia,
  • Giuseppe Morana,
  • Vincenzo Patruno,
  • Giorgio Monteleone,
  • Nicolò Reccardini,
  • Rossella Cifaldi and
  • Barbara Ruaro
  • + 6 authors

22 September 2025

Background/Objectives: Idiopathic pulmonary fibrosis (IPF) is the most common form of pulmonary fibrosis (PF) and serves as a key reference for disease severity. Progressive pulmonary fibrosis (PPF), a distinct yet heterogeneous entity arising from v...

  • Article
  • Open Access
20 Citations
3,714 Views
12 Pages

High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment

  • Elisabetta Balestro,
  • Elisabetta Cocconcelli,
  • Chiara Giraudo,
  • Roberta Polverosi,
  • Davide Biondini,
  • Donato Lacedonia,
  • Erica Bazzan,
  • Linda Mazzai,
  • Giulia Rizzon and
  • Paolo Spagnolo
  • + 5 authors

15 September 2019

Antifibrotic treatment slows down functional decline and disease progression in idiopathic pulmonary fibrosis (IPF). High-resolution computed tomography (HRCT) is useful to diagnose IPF; however, little is known about whether and to what extent HRCT...

  • Feature Paper
  • Review
  • Open Access
3 Citations
5,312 Views
15 Pages

Emergent Peptides of the Antifibrotic Arsenal: Taking Aim at Myofibroblast Promoting Pathways

  • Zhen Liu,
  • Xinyan Zhang,
  • Yanrong Wang,
  • Yifan Tai,
  • Xiaolin Yao and
  • Adam C. Midgley

28 July 2023

Myofibroblasts are the principal effector cells driving fibrosis, and their accumulation in tissues is a fundamental feature of fibrosis. Essential pathways have been identified as being central to promoting myofibroblast differentiation, revealing m...

  • Article
  • Open Access
1 Citations
1,503 Views
14 Pages

AI-Based HRCT Quantification in Connective Tissue Disease-Associated Interstitial Lung Disease

  • Anna Russo,
  • Vittorio Patanè,
  • Alessandra Oliva,
  • Vittorio Viglione,
  • Linda Franzese,
  • Giulio Forte,
  • Vasiliki Liakouli,
  • Fabio Perrotta and
  • Alfonso Reginelli

28 August 2025

Background: Interstitial lung disease (ILD) is a frequent and potentially progressive manifestation in patients with connective tissue diseases (CTDs). Accurate and reproducible quantification of parenchymal abnormalities on high-resolution computed...

  • Article
  • Open Access
27 Citations
5,088 Views
23 Pages

Serial Measurements of Circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and Periostin in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: An Exploratory Study

  • Sebastian Majewski,
  • Karolina Szewczyk,
  • Aleksandra Żal,
  • Adam J. Białas,
  • Joanna Miłkowska-Dymanowska and
  • Wojciech J. Piotrowski

28 August 2021

Idiopathic pulmonary fibrosis (IPF) is a progressive and inevitably fatal disease with a heterogeneous clinical course. This study aimed to evaluate the usefulness of circulating biomarkers in routine IPF clinical practice. We conducted an explorator...

  • Review
  • Open Access
741 Views
24 Pages

Recent Updates on Molecular and Physical Therapies for Organ Fibrosis

  • Michał Filipski,
  • Natalia Libergal,
  • Maksymilian Mikołajczyk,
  • Daria Sznajderowicz,
  • Vitalij Novickij,
  • Augustinas Želvys,
  • Paulina Malakauskaitė,
  • Olga Michel,
  • Julita Kulbacka and
  • Anna Choromańska

13 December 2025

Organ fibrosis is a progressive and often irreversible pathological process characterized by excessive deposition of extracellular matrix, leading to tissue dysfunction and failure. Despite its significant impact on various organ systems, available a...

  • Review
  • Open Access
320 Views
25 Pages

Most Promising Emerging Therapies for Pulmonary Fibrosis: Targeting Novel Pathways

  • Lorenzo Carriera,
  • Roberto Lipsi,
  • Meridiana Dodaj,
  • Riccardo Inchingolo,
  • Andrea Smargiassi,
  • Angelo Coppola,
  • Pier-Valerio Mari,
  • Roberto Barone,
  • Simone Ielo and
  • Luca Richeldi
  • + 1 author

Interstitial lung diseases (ILDs) encompass a heterogeneous group of disorders characterized by varying degrees of inflammation and fibrosis. Despite advances in understanding the pathogenesis, therapeutic options remain limited, particularly for pat...

  • Review
  • Open Access
1,017 Citations
53,689 Views
43 Pages

Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives

  • Natascha Roehlen,
  • Emilie Crouchet and
  • Thomas F. Baumert

3 April 2020

Liver fibrosis due to viral or metabolic chronic liver diseases is a major challenge of global health. Correlating with liver disease progression, fibrosis is a key factor for liver disease outcome and risk of hepatocellular carcinoma (HCC). Despite...

  • Feature Paper
  • Review
  • Open Access
5 Citations
4,104 Views
12 Pages

23 October 2023

Systemic sclerosis (SSc) is an autoimmune connective tissue disease characterized by immune dysregulation and progressive fibrosis, typically affecting the skin, with variable internal organ involvement. Interstitial lung disease (ILD), with a preval...

  • Article
  • Open Access
39 Citations
4,312 Views
13 Pages

Association between Circular RNA CDR1as and Post-Infarction Cardiac Function in Pig Ischemic Heart Failure: Influence of the Anti-Fibrotic Natural Compounds Bufalin and Lycorine

  • Julia Mester-Tonczar,
  • Johannes Winkler,
  • Patrick Einzinger,
  • Ena Hasimbegovic,
  • Nina Kastner,
  • Dominika Lukovic,
  • Katrin Zlabinger,
  • Andreas Spannbauer,
  • Denise Traxler and
  • Mariann Gyöngyösi
  • + 2 authors

14 August 2020

Anti-fibrotic therapies are of increasing interest to combat cardiac remodeling and heart failure progression. Recently, anti-fibrotic circular RNAs (circRNAs) have been identified in human and rodent cardiac tissue. In vivo (rodent) experiments prov...

  • Review
  • Open Access
1,019 Views
22 Pages

Radiation-Induced Fibrosis (RIF) in Head and Neck Squamous Cell Carcinoma (HNSCC): A Review

  • Molly E. Muehlebach,
  • Sidharth Pradeep,
  • Xin Chen,
  • Levi Arnold,
  • Anna E. Arthur,
  • Gregory N. Gan and
  • Sufi Mary Thomas

11 December 2025

Radiation-induced fibrosis (RIF) refers to the aberrant and continuous induction of myofibroblast-mediated wound healing in response to radiation therapy (RT) and occurs in up to 50% of head and neck squamous cell carcinoma (HNSCC) patients post-RT....

  • Article
  • Open Access
1,019 Views
16 Pages

The Role of Antifibrotic Therapy in Pulmonary Fibrosis and Lung Cancer: A Multicenter Retrospective Analysis

  • Francesco Rocco Bertuccio,
  • Nicola Baio,
  • Fabio Perrotta,
  • Donato Lacedonia,
  • Vito D’Agnano,
  • Andrea Bianco,
  • Giulia Scioscia,
  • Pasquale Tondo,
  • Maria Pia Foschino Barbaro and
  • Giulia Maria Stella
  • + 2 authors

21 September 2025

Background: Patients with fibrotic interstitial lung disease (ILD) are at increased risk of lung cancer, yet the impact of antifibrotic therapy on oncologic outcomes remains unclear. Objective: This study aimed to explore associations between antifib...

  • Review
  • Open Access
71 Citations
10,296 Views
27 Pages

24 November 2019

Fibrogenesis is a progressive scarring event resulting from disrupted regular wound healing due to repeated tissue injury and can end in organ failure, like in liver cirrhosis. The protagonists in this process, either liver-resident cells or patrolli...

  • Case Report
  • Open Access
1 Citations
2,864 Views
15 Pages

Fibrotic Hypersensitivity Pneumonitis: A Diagnostic Challenge Leading to Lung Transplantation

  • Maria-Daniela Mot,
  • Dana Cristina Olar,
  • Paula Alexandra Vulciu,
  • Paula-Irina Barata,
  • Ana-Liana Bouros-Tataru,
  • Denis Bogdan Butari,
  • Florin Mihai Șandor and
  • Laura Ioana Bondar

Background/Objectives: Hypersensitivity pneumonitis (HP), a subtype of interstitial lung disease (ILD), is often misdiagnosed as idiopathic pulmonary fibrosis (IPF), particularly when the causative antigen cannot be identified. Typically resulting fr...

  • Review
  • Open Access
31 Citations
8,372 Views
12 Pages

25 May 2021

Progressive fibrosing interstitial lung disease (PF-ILD) describes a phenotypic subset of interstitial lung diseases characterized by progressive, intractable lung fibrosis. PF-ILD is separate from, but has radiographic, histopathologic, and clinical...

  • Article
  • Open Access
12 Citations
3,829 Views
11 Pages

Dendropanoxide, a Triterpenoid from Dendropanax morbifera, Ameliorates Hepatic Fibrosis by Inhibiting Activation of Hepatic Stellate Cells through Autophagy Inhibition

  • Yong-Joo Park,
  • Dong-Min Kim,
  • Hye-Been Choi,
  • Mi-Ho Jeong,
  • Seung-Hwan Kwon,
  • Ha-Ryong Kim,
  • Jong-Hwan Kwak and
  • Kyu-Hyuck Chung

27 December 2021

Hepatic fibrosis results from chronic liver damage and is characterized by excessive accumulation of extracellular matrix (ECM). In this study, we showed that dendropanoxide (DPX), isolated from Dendropanax morbifera, had anti-fibrotic effects on hep...

  • Article
  • Open Access
946 Views
12 Pages

Effects of Antifibrotic Therapy in Patients with Combined Pulmonary Fibrosis and Emphysema: A US-Based Cohort Study

  • Abhishek Shah,
  • Esteban Kosak Lopez,
  • Andrew Geller,
  • Maanav Patel and
  • Sadia Benzaquen

Background/Objectives: Combined pulmonary fibrosis and emphysema (CPFE) is associated with poor outcomes. We investigated the association of antifibrotic therapy on patients with CPFE. Methods: This retrospective study included adult patients, older...

  • Review
  • Open Access
71 Citations
14,767 Views
20 Pages

20 October 2022

Liver fibrosis results from repeated and persistent liver damage. It can start with hepatocyte injury and advance to inflammation, which recruits and activates additional liver immune cells, leading to the activation of the hepatic stellate cells (HS...

  • Article
  • Open Access
3 Citations
2,760 Views
9 Pages

Perioperative Anti-Fibrotic Treatment Prevents Acute Exacerbation of Idiopathic Pulmonary Fibrosis After Lung Cancer Surgery

  • Stefano Bongiolatti,
  • Alberto Salvicchi,
  • Elisabetta Rosi,
  • Elena Bargagli,
  • Giovanni Mugnaini,
  • Alessandro Gonfiotti,
  • Federico Lavorini,
  • Paolo Spagnolo,
  • Andrea Dell’Amore and
  • Luca Voltolini
  • + 1 author

19 November 2024

Background: The surgical treatment of concomitant lung cancer in patients with idiopathic pulmonary fibrosis is challenging due to the risk of life-threatening complications such as acute exacerbation development in the perioperative period. Few stud...

  • Article
  • Open Access
5 Citations
3,241 Views
17 Pages

Ameliorating Fibrosis in Murine and Human Tissues with END55, an Endostatin-Derived Fusion Protein Made in Plants

  • Logan Mlakar,
  • Sara M. Garrett,
  • Tomoya Watanabe,
  • Matthew Sanderson,
  • Tetsuya Nishimoto,
  • Jonathan Heywood,
  • Kristi L. Helke,
  • Joseph M. Pilewski,
  • Erica L. Herzog and
  • Carol Feghali-Bostwick

Organ fibrosis, particularly of the lungs, causes significant morbidity and mortality. Effective treatments are needed to reduce the health burden. A fragment of the carboxyl-terminal end of collagen XVIII/endostatin reduces skin and lung fibrosis. T...

  • Article
  • Open Access
15 Citations
3,825 Views
11 Pages

Blood Immunophenotypes of Idiopathic Pulmonary Fibrosis: Relationship with Disease Severity and Progression

  • Nuria Mendoza,
  • Sandra Casas-Recasens,
  • Núria Olvera,
  • Fernanda Hernandez-Gonzalez,
  • Tamara Cruz,
  • Núria Albacar,
  • Xavier Alsina-Restoy,
  • Alejandro Frino-Garcia,
  • Gemma López-Saiz and
  • Rosa Faner
  • + 4 authors

7 September 2023

(1) The role of the immune response in the pathogenesis of idiopathic pulmonary fibrosis (IPF) remains controversial. We hypothesized that peripheral blood immune phenotypes will be different in IPF patients and may relate to the disease severity and...

  • Review
  • Open Access
3 Citations
5,322 Views
23 Pages

22 May 2024

Fibrosing interstitial lung diseases (FILDs), e.g., due to idiopathic pulmonary fibrosis (IPF), are chronic progressive diseases with a poor prognosis. The management of these diseases is challenging and focuses mainly on the suppression of progressi...

  • Review
  • Open Access
36 Citations
8,461 Views
31 Pages

Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis

  • Anshika Jangra,
  • Ashish Kothari,
  • Phulen Sarma,
  • Bikash Medhi,
  • Balram Ji Omar and
  • Karanvir Kaushal

29 April 2022

Cirrhosis is a severe form of liver fibrosis that results in the irreversible replacement of liver tissue with scar tissue in the liver. Environmental toxicity, infections, metabolic causes, or other genetic factors including autoimmune hepatitis can...

  • Review
  • Open Access
25 Citations
7,963 Views
14 Pages

Fibro-Stenosing Crohn’s Disease: What Is New and What Is Next?

  • Virginia Solitano,
  • Arianna Dal Buono,
  • Roberto Gabbiadini,
  • Marek Wozny,
  • Alessandro Repici,
  • Antonino Spinelli,
  • Stefania Vetrano and
  • Alessandro Armuzzi

22 April 2023

Fibro-stenosing Crohn’s disease (CD) is a common disease presentation that leads to impaired quality of life and often requires endoscopic treatments or surgery. From a pathobiology perspective, the conventional view that intestinal fibro-steno...

  • Article
  • Open Access
17 Citations
3,902 Views
22 Pages

12 August 2022

Background: Although intestinal fibrosis is a consequence of recurrent inflammation in Inflammatory bowel disease (IBD), alleviating inflammation alone does not prevent the progression of fibrosis, suggesting that the development of direct anti-fibro...

  • Feature Paper
  • Review
  • Open Access
1 Citations
5,110 Views
13 Pages

The Promise of Single-Cell RNA Sequencing to Redefine the Understanding of Crohn’s Disease Fibrosis Mechanisms

  • Iona Campbell,
  • Michael Glinka,
  • Fadlo Shaban,
  • Kathryn J. Kirkwood,
  • Francesca Nadalin,
  • David Adams,
  • Irene Papatheodorou,
  • Albert Burger,
  • Richard A. Baldock and
  • Shahida Din
  • + 1 author

7 June 2023

Crohn’s disease (CD) is a chronic inflammatory bowel disease with a high prevalence throughout the world. The development of Crohn’s-related fibrosis, which leads to strictures in the gastrointestinal tract, presents a particular challeng...

  • Article
  • Open Access
2,903 Views
19 Pages

A Novel In Vitro Potency Assay Demonstrating the Anti-Fibrotic Mechanism of Action of CDCs in Deramiocel

  • Yujia Li,
  • Justin B. Nice,
  • Marya Kozinova,
  • Stephanie Adachi,
  • Linda Marbán,
  • Kristi Elliott and
  • Minghao Sun

Background/Objectives: Duchenne muscular dystrophy (DMD) is characterized by progressive skeletal and cardiac muscle degeneration driven by inflammation and fibrosis, ultimately leading to cardiomyopathy and premature death. Deramiocel, an allogeneic...

of 9